SLNCF — Stock Film
STOCK FILMSCENE 1/11SLNCF · $5.50
Stock Expert AI presents
SLNCF
Silence Therapeutics plc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Silence Therapeutics plc. A quick introduction.

On the stock market since 2012, it operates in the world of health and science. It has 88 employees. Now — the numbers.

on the stock market since 2012
88 employees
$648.3M market value
Revenue last year:
$0
The loss that same year:
$0
For every $1 it earns, the company spends $160.

The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.

THE SALES TREND
Sales have been shrinking.

An average decline of 54% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.

$12.4M
2021
$17.5M
2022
$25.4M
2023
$43.3M
2024
$559K
2025
In the vault right now:
$0
DEBT: -$160K
At this pace, that money lasts less than a year.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

Every quarter, analysts set a profit bar.
How many of the last 8 did the company clear?
2 / 8
EXPECTATIONS MET OR BEATEN
2
Nov 2024
Feb 2025
May 2025
Aug 2025
Nov 2025
Mar 2026
May 2026
Aug 2026
2 TIMES IN THE LAST 8 QUARTERS
It misses the bar more often than not.
THE COUNCIL REVIEW
9

angles, checked one by one.

The 4 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Heavy investment in the future10/10
WEAK SPOTS
Growth has stalled2/10
Heavy bets against the stock2/10
Costs eat into the margin4/10
WORTH WATCHING

Revenue Growth: Sales are growing slowly.

THE FIVE-YEAR JOURNEY
A big climb, then a hard fall.

An investor who bought at the very peak is down 82% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

THE BRIGHT SIDE

Nothing in the current numbers stands out as a strong positive. That, by itself, is worth knowing.

1
THE RISKS · 1/2
Small sales, big loss

A loss of $88.6M against $559K in annual sales. And on top of that, sales fell from the year before.

2
THE RISKS · 2/2
The cash has a countdown

At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.

FINALE · THE GRADE
D
0 / 100 · MoonshotScore

On our five-subject report card, SLNCF sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: SLNCF is a small company that closed last year at a loss. The road back to profit runs through spending discipline.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 21, 2026 · stockexpertai.com · Stock Film